Kratz Barry LLP

General

Please sign up or log in to access the advanced features of
Ex Parte Professional.

or Log in

Cases70

Challenger50%

Patent Owner50%

NPE50%

Practice Areas

BiotechReexam/Aband.Transport., E-Comm.

Top Attorneys

Patrick J. CoyneNeal S. CohenPeter Kinsella

Elite Ratings

DCTPTABCAFC

Ratings

Please sign up or log in to access the advanced features of
Ex Parte Professional.

or Log in

Experience

Grade

Trend

DCT

PTAB

CAFC

Analytics

Lawyers

Cases

Ratings Trends

Practice Areas

Recent Dockets

Entered	Case	Description
09/16/24	Theravance Biopharma R&D IP LLC v. Eugia Pharma Specialties Ltd 1:23-CV-00926 ( D. NJ )	Letter from Arnold B. Calmann, Esq. to the Honorable Karen M. Williams, U.S.D.J. and the Honorable Ann Marie Donio, U.S.M.J. Regarding Eugia's Motion for Summary Judgment re [270] Letter,,. (CALMANN, ARNOLD)NOTICE TO COUNSEL: Counsel is advised that pursuant to Local Civil Rule 5.3(c)(2), a single, consolidated motion to seal shall be filed within 14 days following the completed briefing of the materials sought to be sealed, or within 14 days following the date on which the last of such materials was filed under temporary seal if the motion is resolved, unless otherwise directed by the Court. (Entered: 09/16/2024) Letter from Arnold B. Calmann, Esq. to the Honorable Karen M. Williams, U.S.D.J. and the Honorable Ann Marie Donio, U.S.M.J. Regarding Eugia's Motion for Summary Judgment re [270] Letter,,. (CALMANN, ARNOLD)NOTICE TO COUNSEL: Counsel is advised that pursuant to Local Civil Rule 5.3(c)(2), a single, consolidated motion to seal shall be filed within 14 days following the completed briefing of the materials sought to be sealed, or within 14 days following the date on which the last of such materials was filed under temporary seal if the motion is resolved, unless otherwise directed by the Court. (Entered: 09/16/2024)
09/16/24	In re: Entresto (Sacubitril/Valsartan) Patent Litigation 1:20-MD-02930 ( D. DE )	REDACTED VERSION of [1528] Letter, by Gerbera Therapeutics Inc., Nanjing Noratech Pharmaceutical Co., Limited. (Attachments: # [1] Exhibit G, # [2] Exhibit H, # [3] Exhibit I)(Gattuso, Dominick) (Entered: 09/16/2024)
09/16/24	In re: Xarelto (Rivaroxaban) ('310) Patent Litigation 1:21-MD-03017 ( D. DE )	REDACTION NOTICE: In accordance with section G of the Administrative Procedures Governing Filing and Service by Electronic Means, redacted versions of sealed documents shall be filed electronically within 7 days of the filing of the sealed document. The records of this case do not reflect the filing of a redacted version of DI # [297] . (nms) (Entered: 09/16/2024)
09/16/24	In re: Entresto (Sacubitril/Valsartan) Patent Litigation 1:20-MD-02930 ( D. DE )	DEFICIENCY NOTICE by the Court issued to Gerbera Therapeutics, Inc. and Nanjing Noratech Pharmaceutical Co. Limited re [1539] Redacted Document. Upon review it was determined this filing was not a complete version of what was filed at D.I. [1528] . The redaction lacked Exhibit I. Defendants are to file a revised redacted version of D.I. [1528] no later than three (3) days from the date of this notice. (nms) (Entered: 09/16/2024) DEFICIENCY NOTICE by the Court issued to Gerbera Therapeutics, Inc. and Nanjing Noratech Pharmaceutical Co. Limited re [1539] Redacted Document. Upon review it was determined this filing was not a complete version of what was filed at D.I. [1528] . The redaction lacked Exhibit I. Defendants are to file a revised redacted version of D.I. [1528] no later than three (3) days from the date of this notice. (nms) (Entered: 09/16/2024)
09/12/24	Acadia Pharmaceuticals Inc v. Aurobindo Pharma Ltd 1:22-CV-01387 ( D. DE )	[SEALED] OPENING BRIEF in Support re [94] MOTION in Limine Regarding Certain Opinions of Dr. Pamela Smith filed by MSN Laboratories Private Ltd..Answering Brief/Response due date per Local Rules is 9/26/2024. (Attachments: # [1] Exhibit Exhibit A to Declaration, # [2] Exhibit Exhibit B to Declaration, # [3] Exhibit Exhibit C to Declaration)(Green, James) (Entered: 09/12/2024)
09/12/24	Acadia Pharmaceuticals Inc v. Aurobindo Pharma Ltd 1:22-CV-01387 ( D. DE )	MOTION in Limine Regarding Certain Opinions of Dr. Pamela Smith - filed by MSN Laboratories Private Ltd.. (Attachments: # [1] Proposed Order)(Green, James) (Entered: 09/12/2024)
09/12/24	Amicus Therapeutics US LLC v. Teva Pharmaceuticals USA Inc 1:22-CV-01461 ( D. DE )	NOTICE OF SERVICE of (1) Defendants, Aurobindo Pharma Ltd. and Aurobindo Pharma USA, Inc.s Responses and Objections to Plaintiffs First Set of Requests for Admission (Nos. 1-11); (2) Defendants, Aurobindo Pharma Ltd. and Aurobindo Pharma USA, Inc.s Responses and Objections to Plaintiffs Fourth Set of Interrogatories (Nos. 15-17); and (3) Defendants, Aurobindo Pharma Ltd. and Aurobindo Pharma USA, Inc.s Responses and Objections to Plaintiffs Notice of Deposition Pursuant to Fed. R. Civ. P. 30(b)(6) filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc..(Myer, R.) (Entered: 09/12/2024) NOTICE OF SERVICE of (1) Defendants, Aurobindo Pharma Ltd. and Aurobindo Pharma USA, Inc.s Responses and Objections to Plaintiffs First Set of Requests for Admission (Nos. 1-11); (2) Defendants, Aurobindo Pharma Ltd. and Aurobindo Pharma USA, Inc.s Responses and Objections to Plaintiffs Fourth Set of Interrogatories (Nos. 15-17); and (3) Defendants, Aurobindo Pharma Ltd. and Aurobindo Pharma USA, Inc.s Responses and Objections to Plaintiffs Notice of Deposition Pursuant to Fed. R. Civ. P. 30(b)(6) filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc..(Myer, R.) (Entered: 09/12/2024)
09/09/24	Axsome Malta Ltd v. Alkem Laboratories Ltd 2:23-CV-20354 ( D. NJ )	STIPULATION AND ORDER of Dismissal regarding Defendant, SANDOZ INC.. SANDOZ INC. terminated. Signed by Judge Madeline Cox Arleo on 9/9/2024. (jd, ) (Entered: 09/09/2024)
08/05/24	Intra Cellular Therapies Inc v. Alkem Laboratories Ltd 3:24-CV-04312 ( D. NJ )	Text Order: Pursuant to the Court's discussion with counsel during the initial scheduling conference, the Clerk is directed to effect the consolidation order previously entered on July 16, 2024 (Dkt. 22 ) so that: (i) all local counsel of record in the seven consolidated actions are listed as counsel of record in Civil Action No. 24-4264 and receive notification of filings in that action; (ii) Civil Action No. 24-4264 is treated as the lead consolidated action; and (iii) that in light of the consolidation, the other six actions (Civil Action Nos. 24-4312; 24-4314; 24-4317; 24-4325; 24-4327; and 24-4330) be administratively closed. For clarity and avoidance of doubt, all parties have reserved the right to request separate joint or separate trials pursuant to Rule 42(b). So Ordered by Magistrate Judge J. Brendan Day on 8/5/2024. (eaj) (Entered: 08/05/2024) Text Order: Pursuant to the Court's discussion with counsel during the initial scheduling conference, the Clerk is directed to effect the consolidation order previously entered on July 16, 2024 (Dkt. 22 ) so that: (i) all local counsel of record in the seven consolidated actions are listed as counsel of record in Civil Action No. 24-4264 and receive notification of filings in that action; (ii) Civil Action No. 24-4264 is treated as the lead consolidated action; and (iii) that in light of the consolidation, the other six actions (Civil Action Nos. 24-4312; 24-4314; 24-4317; 24-4325; 24-4327; and 24-4330) be administratively closed. For clarity and avoidance of doubt, all parties have reserved the right to request separate joint or separate trials pursuant to Rule 42(b). So Ordered by Magistrate Judge J. Brendan Day on 8/5/2024. (eaj) (Entered: 08/05/2024)
08/05/24	Intra Cellular Therapies Inc v. Alkem Laboratories Ltd 3:24-CV-04312 ( D. NJ )	***Civil Case Administratively Terminated. (eaj, ) (Entered: 08/05/2024)